Zhi-Kang Ye1, Yao-Long Chen2,3, Ken Chen1, Xiang-Lin Zhang4, Guan-Hua Du5, Bei He6, Da-Kui Li7, You-Ning Liu8, Ke-Hu Yang2,3, Ying-Yuan Zhang9, Suo-Di Zhai10. 1. Department of Pharmacy, Peking University Third Hospital, Beijing, China. 2. Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Gansu, China. 3. Chinese GRADE Center, Gansu, China. 4. Pharmaceutical Department of China-Japan Friendship Hospital, Beijing, China. 5. Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing, China. 6. Department of Respiratory Medicine, Peking University Third Hospital, Beijing, China. 7. Pharmacy Department, Peking Union Medical College Hospital, Beijing, China. 8. Institute of Respiratory Disease, Chinese PLA General Hospital, Beijing, China. 9. Institute of Antibiotics, Huashan Hospital Affiliated to Fudan University, Shanghai, China. 10. Department of Pharmacy, Peking University Third Hospital, Beijing, China zhaisuodi@163.com.
Abstract
BACKGROUND: Guideline development should be based on the quality of evidence, balance of benefits and harms, economic evaluation and patients' views and preferences. Therefore, these factors were considered in the development of a new guideline for therapeutic drug monitoring (TDM) of vancomycin. OBJECTIVES: To develop an evidence-based guideline for vancomycin TDM and to promote standardized vancomycin TDM in clinical practice in China. METHODS: We referred to the WHO Handbook for Guideline Development and used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system to rate the quality of evidence and grade the strength of recommendations, according to economic evaluation and patients' views and preferences. We used the GRADE Grid method to formulate the recommendations. RESULTS: The guideline presents recommendations about who should receive vancomycin TDM, how to monitor vancomycin efficacy and renal safety, therapeutic trough concentrations, time to start initial vancomycin TDM, loading dose and how to administer and adjust the vancomycin dose. CONCLUSIONS: We developed an evidence-based guideline for vancomycin TDM, which provides recommendations for clinicians and pharmacists to conduct vancomycin TDM in China.
BACKGROUND: Guideline development should be based on the quality of evidence, balance of benefits and harms, economic evaluation and patients' views and preferences. Therefore, these factors were considered in the development of a new guideline for therapeutic drug monitoring (TDM) of vancomycin. OBJECTIVES: To develop an evidence-based guideline for vancomycin TDM and to promote standardized vancomycin TDM in clinical practice in China. METHODS: We referred to the WHO Handbook for Guideline Development and used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system to rate the quality of evidence and grade the strength of recommendations, according to economic evaluation and patients' views and preferences. We used the GRADE Grid method to formulate the recommendations. RESULTS: The guideline presents recommendations about who should receive vancomycin TDM, how to monitor vancomycin efficacy and renal safety, therapeutic trough concentrations, time to start initial vancomycin TDM, loading dose and how to administer and adjust the vancomycin dose. CONCLUSIONS: We developed an evidence-based guideline for vancomycin TDM, which provides recommendations for clinicians and pharmacists to conduct vancomycin TDM in China.
Authors: Tatjana Van Der Heggen; Franky M Buyle; Barbara Claus; Annemie Somers; Petra Schelstraete; Peter De Paepe; Sophie Vanhaesebrouck; Pieter A J G De Cock Journal: Int J Clin Pharm Date: 2021-04-28